Luxturna gene therapy approved for vision loss

eye x

The first two novel gene therapies for cancer treatment passed through FDA approval earlier this year, first B-cell acute lymphoblastic leukemia (ALL) followed quickly by Yescarta for large B-cell lymphoma – a type of non-Hodgkin lymphoma.

One more gene therapy squeaked in before year’s end, not for cancer treatment, but an inherited form of vision loss that can lead to blindness called biallelic RPE65 mutation-associated retinal dystrophy. The treatment is called Luxturna.

…

The RPE65 gene, named for it’s location of expression in the eye, the retinal pigment epithelium or RPE, is responsible for making the enzyme isomerohydrolase which is responsible for making rhodopsin, a molecule necessary for normal vision. Mutations in RPE65 block this process and result in impaired vision.

Luxterna delivers a normal, non-mutated, copy of the RPE65 gene directly to the cells of the retina. This allows the enzyme to be made and restores vision. In the Phase 3 study, 31 participants were asked to navigate an obstacle course at various light levels. Navigating in the low light settings was significantly improved in the patients who received Luxterna.

…

With two cancer therapies approved last year, and now a third therapy for vision, 2017 has paved the way for many more that will most certainly be coming down the pike in 2018.

Read full, original post: One More Gene Therapy Approved Before Year’s End

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-11-17-at-12.18.09-PM
Challenging glyphosate fear-mongering: Statewide Nebraska study finds no link between weedkiller use and non-Hodgkin lymphoma
Soybean Harvest in Cupped Hands
30 years of GMO farming: Defying cynics, we’ve had larger harvests, lower costs, and $385 billion in added global farmer income
Screenshot-2026-11-18-at-2.44.24-PM
Why should thousands of Americans die every year waiting for a kidney transplant? There’s an easy fix to this morbid reality
Health vs
Health vs. Hype’s rocky debut: American Medical Association’s misinformation-debunking podcast platforms ‘leaky gut’ wellness crank 
Low-Poly Climate Connections Infographic
Viewpoint: EU-backed climate “disinformation” crackdown—who polices what’s false?
measles
The grim human cost of the Trump—RFK Jr. measles-prevention failure: 16 times more cases than in 2024
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
Gloved Hand Holding M-M-R Vaccine Vial
Viewpoint: The dangerous lie RFK Jr.-founded Children’s Health Defense is circulating to discredit one of medicine’s great breakthroughs: the MMR (measles-mumps-rubella) vaccine
BEMT Lotion for Freckled Skin
Burned by FDA bureaucracy: Why Americans waited decades for cancer-preventing sunscreen
Screenshot-2026-11-17-at-12.56.22-PM
RFK Jr.’s CDC blocked measles risk alert for pregnant women; 112 contracted the disease, and one-quarter were hospitalized
Screenshot-2026-11-17-at-11.04.14-AM
There are more than 6,000 genetic disorders. For the first time, gene editing is making some treatable. Are we ready?
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.